Phreesia (PHR) Stock Price
Phreesia Price
Revenue has compounded at 26.4% per year over the past 8 years to 473.64 M USD. Phreesia's net margin stands at 0.5%, up from -56.0% several years earlier. Analysts set a median price target of 28.56 USD, implying 166.2% above the current price. Of 24 analysts, 23 rate the stock a buy — an overall Buy consensus. The stock trades about 33% above its 52-week low.
Phreesia stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Phreesia over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Phreesia stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Phreesia's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Phreesia Price |
|---|---|
| 7/31/2026 | 10.73 USD |
| 7/30/2026 | 10.61 USD |
| 7/29/2026 | 11.05 USD |
| 7/27/2026 | 10.77 USD |
| 7/23/2026 | 9.80 USD |
| 7/22/2026 | 10.01 USD |
| 7/21/2026 | 10.60 USD |
| 7/20/2026 | 10.68 USD |
| 7/17/2026 | 10.71 USD |
| 7/16/2026 | 10.89 USD |
| 7/15/2026 | 10.76 USD |
| 7/14/2026 | 10.74 USD |
| 7/13/2026 | 11.10 USD |
| 7/10/2026 | 10.72 USD |
| 7/9/2026 | 10.82 USD |
| 7/8/2026 | 10.64 USD |
| 7/7/2026 | 10.95 USD |
| 7/6/2026 | 10.79 USD |
| 7/2/2026 | 10.94 USD |
| 7/1/2026 | 10.72 USD |
| 6/30/2026 | 10.29 USD |
| 6/29/2026 | 9.91 USD |
| 6/26/2026 | 10.07 USD |
| 6/25/2026 | 9.13 USD |
| 6/24/2026 | 9.59 USD |
| 6/23/2026 | 9.15 USD |
| 6/22/2026 | 9.06 USD |
| 6/18/2026 | 9.45 USD |
| 6/17/2026 | 9.50 USD |
| 6/16/2026 | 9.30 USD |
| 6/15/2026 | 9.27 USD |
| 6/12/2026 | 9.02 USD |
| 6/11/2026 | 8.93 USD |
| 6/10/2026 | 9.20 USD |
| 6/9/2026 | 9.29 USD |
| 6/8/2026 | 9.34 USD |
| 6/5/2026 | 9.42 USD |
| 6/4/2026 | 9.89 USD |
| 6/3/2026 | 9.67 USD |
| 6/2/2026 | 10.22 USD |
| 6/1/2026 | 10.30 USD |
| 5/29/2026 | 9.43 USD |
| 5/28/2026 | 9.59 USD |
| 5/27/2026 | 9.06 USD |
| 5/26/2026 | 8.90 USD |
| 5/22/2026 | 8.85 USD |
| 5/21/2026 | 8.69 USD |
| 5/20/2026 | 8.73 USD |
| 5/19/2026 | 9.17 USD |
| 5/18/2026 | 9.08 USD |
| 5/15/2026 | 8.77 USD |
| 5/14/2026 | 8.77 USD |
| 5/13/2026 | 9.19 USD |
| 5/12/2026 | 9.61 USD |
| 5/11/2026 | 9.57 USD |
| 5/8/2026 | 10.17 USD |
| 5/7/2026 | 9.83 USD |
| 5/6/2026 | 9.53 USD |
| 5/5/2026 | 9.65 USD |
| 5/4/2026 | 9.67 USD |
| 5/1/2026 | 9.67 USD |
| 4/30/2026 | 9.21 USD |
| 4/29/2026 | 9.37 USD |
| 4/28/2026 | 9.42 USD |
| 4/27/2026 | 9.62 USD |
| 4/24/2026 | 9.54 USD |
| 4/23/2026 | 8.91 USD |
| 4/22/2026 | 9.32 USD |
| 4/21/2026 | 9.36 USD |
| 4/20/2026 | 9.43 USD |
| 4/17/2026 | 9.17 USD |
| 4/16/2026 | 9.17 USD |
| 4/15/2026 | 9.06 USD |
| 4/14/2026 | 8.60 USD |
| 4/13/2026 | 8.56 USD |
| 4/10/2026 | 8.06 USD |
| 4/9/2026 | 8.09 USD |
| 4/8/2026 | 8.75 USD |
| 4/7/2026 | 9.06 USD |
| 4/6/2026 | 9.15 USD |
| 4/2/2026 | 8.37 USD |
| 4/1/2026 | 8.40 USD |
| 3/31/2026 | 8.38 USD |
| 3/30/2026 | 11.41 USD |
| 3/27/2026 | 10.98 USD |
| 3/26/2026 | 11.65 USD |
| 3/25/2026 | 11.28 USD |
| 3/24/2026 | 11.28 USD |
| 3/23/2026 | 11.80 USD |
| 3/20/2026 | 11.86 USD |
| 3/19/2026 | 11.77 USD |
| 3/18/2026 | 11.20 USD |
| 3/17/2026 | 11.19 USD |
| 3/16/2026 | 10.99 USD |
| 3/13/2026 | 10.97 USD |
| 3/12/2026 | 11.00 USD |
| 3/11/2026 | 11.34 USD |
| 3/10/2026 | 11.75 USD |
| 3/9/2026 | 12.06 USD |
| 3/6/2026 | 12.05 USD |
| 3/5/2026 | 12.08 USD |
| 3/4/2026 | 12.63 USD |
| 3/3/2026 | 12.37 USD |
| 3/2/2026 | 12.27 USD |
| 2/27/2026 | 12.33 USD |
| 2/26/2026 | 12.33 USD |
| 2/25/2026 | 11.83 USD |
| 2/24/2026 | 11.66 USD |
| 2/23/2026 | 11.70 USD |
| 2/20/2026 | 12.71 USD |
| 2/19/2026 | 12.58 USD |
| 2/18/2026 | 12.10 USD |
| 2/17/2026 | 11.83 USD |
| 2/13/2026 | 11.95 USD |
| 2/12/2026 | 11.86 USD |
| 2/11/2026 | 12.50 USD |
| 2/10/2026 | 12.41 USD |
| 2/9/2026 | 12.22 USD |
| 2/6/2026 | 12.20 USD |
| 2/5/2026 | 12.59 USD |
| 2/4/2026 | 12.83 USD |
| 2/3/2026 | 12.78 USD |
| 2/2/2026 | 13.21 USD |
| 1/30/2026 | 13.43 USD |
| 1/29/2026 | 13.95 USD |
| 1/28/2026 | 14.66 USD |
| 1/27/2026 | 15.19 USD |
| 1/26/2026 | 15.72 USD |
| 1/23/2026 | 15.84 USD |
| 1/22/2026 | 15.80 USD |
| 1/21/2026 | 15.62 USD |
| 1/20/2026 | 15.73 USD |
| 1/16/2026 | 16.39 USD |
| 1/15/2026 | 16.45 USD |
| 1/14/2026 | 16.11 USD |
| 1/13/2026 | 16.58 USD |
| 1/12/2026 | 17.14 USD |
| 1/9/2026 | 17.23 USD |
| 1/8/2026 | 16.90 USD |
| 1/7/2026 | 17.52 USD |
| 1/6/2026 | 17.24 USD |
| 1/5/2026 | 17.12 USD |
| 1/2/2026 | 16.30 USD |
| 12/31/2025 | 16.92 USD |
| 12/30/2025 | 17.03 USD |
| 12/29/2025 | 17.00 USD |
| 12/26/2025 | 17.02 USD |
| 12/24/2025 | 16.81 USD |
| 12/23/2025 | 16.78 USD |
| 12/22/2025 | 16.47 USD |
| 12/19/2025 | 16.55 USD |
| 12/18/2025 | 16.41 USD |
| 12/17/2025 | 16.30 USD |
| 12/16/2025 | 16.35 USD |
| 12/15/2025 | 16.70 USD |
| 12/12/2025 | 16.25 USD |
| 12/11/2025 | 16.04 USD |
| 12/10/2025 | 15.78 USD |
| 12/9/2025 | 15.43 USD |
| 12/8/2025 | 20.12 USD |
| 12/5/2025 | 20.29 USD |
| 12/4/2025 | 20.55 USD |
| 12/3/2025 | 20.38 USD |
| 12/2/2025 | 20.15 USD |
| 12/1/2025 | 20.01 USD |
| 11/28/2025 | 20.49 USD |
| 11/26/2025 | 20.53 USD |
| 11/25/2025 | 20.62 USD |
| 11/24/2025 | 20.28 USD |
| 11/21/2025 | 20.05 USD |
| 11/20/2025 | 19.05 USD |
| 11/19/2025 | 19.19 USD |
| 11/18/2025 | 19.60 USD |
| 11/17/2025 | 20.60 USD |
| 11/14/2025 | 21.77 USD |
| 11/13/2025 | 22.53 USD |
| 11/12/2025 | 23.15 USD |
| 11/11/2025 | 22.75 USD |
| 11/10/2025 | 22.62 USD |
| 11/7/2025 | 22.02 USD |
| 11/6/2025 | 22.27 USD |
| 11/5/2025 | 22.67 USD |
| 11/4/2025 | 22.54 USD |
| 11/3/2025 | 22.73 USD |
| 10/31/2025 | 22.64 USD |
| 10/30/2025 | 22.66 USD |
| 10/29/2025 | 23.22 USD |
| 10/28/2025 | 23.41 USD |
| 10/27/2025 | 23.47 USD |
| 10/24/2025 | 23.48 USD |
| 10/23/2025 | 23.49 USD |
| 10/22/2025 | 23.45 USD |
| 10/21/2025 | 23.11 USD |
| 10/20/2025 | 22.94 USD |
| 10/17/2025 | 22.29 USD |
| 10/16/2025 | 22.75 USD |
| 10/15/2025 | 22.93 USD |
| 10/14/2025 | 22.90 USD |
| 10/13/2025 | 22.24 USD |
| 10/10/2025 | 22.26 USD |
| 10/9/2025 | 23.84 USD |
| 10/8/2025 | 23.25 USD |
| 10/7/2025 | 23.41 USD |
| 10/6/2025 | 23.48 USD |
| 10/3/2025 | 23.27 USD |
| 10/2/2025 | 22.84 USD |
| 10/1/2025 | 22.45 USD |
| 9/30/2025 | 23.52 USD |
| 9/29/2025 | 23.55 USD |
| 9/26/2025 | 23.62 USD |
| 9/25/2025 | 23.45 USD |
| 9/24/2025 | 23.66 USD |
| 9/23/2025 | 23.80 USD |
| 9/22/2025 | 24.74 USD |
| 9/19/2025 | 23.87 USD |
| 9/18/2025 | 24.19 USD |
| 9/17/2025 | 23.28 USD |
| 9/16/2025 | 23.50 USD |
| 9/15/2025 | 23.38 USD |
| 9/12/2025 | 24.19 USD |
| 9/11/2025 | 25.48 USD |
| 9/10/2025 | 25.34 USD |
| 9/9/2025 | 26.55 USD |
| 9/8/2025 | 26.78 USD |
| 9/5/2025 | 28.13 USD |
| 9/4/2025 | 31.21 USD |
| 9/3/2025 | 30.44 USD |
| 9/2/2025 | 31.48 USD |
| 8/29/2025 | 31.66 USD |
| 8/28/2025 | 32.55 USD |
| 8/27/2025 | 31.99 USD |
| 8/26/2025 | 30.80 USD |
| 8/25/2025 | 30.39 USD |
| 8/22/2025 | 29.75 USD |
| 8/21/2025 | 28.76 USD |
| 8/20/2025 | 27.70 USD |
| 8/19/2025 | 28.25 USD |
| 8/18/2025 | 29.10 USD |
| 8/15/2025 | 28.70 USD |
| 8/14/2025 | 28.01 USD |
| 8/13/2025 | 28.65 USD |
| 8/12/2025 | 27.85 USD |
| 8/11/2025 | 27.13 USD |
| 8/8/2025 | 27.01 USD |
| 8/7/2025 | 26.84 USD |
| 8/6/2025 | 27.11 USD |
| 8/5/2025 | 27.10 USD |
Phreesia Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Phreesia Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027e | 2028e | 2029e | 2030e | 2031e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 79.00 | 99.00 | 124.00 | 148.00 | 213.00 | 280.00 | 356.00 | 419.00 | 480.00 | 515.00 | 538.00 | 560.00 | 539.00 | 553.00 |
| – | 25.32 | 25.25 | 19.35 | 43.92 | 31.46 | 27.14 | 17.70 | 14.56 | 7.29 | 4.47 | 4.09 | -3.75 | 2.60 |
| 63.29 | 62.63 | 64.52 | 64.86 | 61.50 | 61.07 | 65.17 | 67.78 | 67.92 | 67.92 | 67.92 | 67.92 | 67.92 | 67.92 |
| 50.00 | 62.00 | 80.00 | 96.00 | 131.00 | 171.00 | 232.00 | 284.00 | 326.00 | 349.77 | 365.39 | 380.33 | 366.07 | 375.58 |
| -15.00 | -9.00 | -19.00 | -25.00 | -116.00 | -176.00 | -136.00 | -58.00 | -4.00 | 235.00 | 245.00 | 255.00 | 246.00 | 252.00 |
| -18.99 | -9.09 | -15.32 | -16.89 | -54.46 | -62.86 | -38.20 | -13.84 | -0.83 | 45.63 | 45.54 | 45.54 | 45.64 | 45.57 |
| -18.00 | -15.00 | -20.00 | -27.00 | -118.00 | -176.00 | -136.00 | -58.00 | 2.00 | 24.00 | 39.00 | 46.00 | 55.00 | 59.00 |
| – | -16.67 | 33.33 | 35.00 | 337.04 | 49.15 | -22.73 | -57.35 | -103.45 | 1,100.00 | 62.50 | 17.95 | 19.57 | 7.27 |
| 28.19 | 35.79 | 38.51 | 51.02 | 52.61 | 55.25 | 57.89 | 61.49 | 62.04 | 62.04 | 62.04 | 62.04 | 62.04 | 62.04 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Phreesia generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Phreesia retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Phreesia's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Phreesia has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Phreesia's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Phreesia stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Phreesia Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Phreesia business model & stock analysis
Phreesia SWOT Analysis
Strengths
Phreesia Inc has a strong market presence and a solid brand reputation in the healthcare industry. The company offers innovative patient intake solutions that streamline administrative processes, allowing healthcare providers to enhance efficiency and patient experience.
Phreesia's technology is user-friendly and provides comprehensive data analytics, empowering healthcare organizations to make informed decisions. The company has a scalable business model and a flexible platform that can be customized to meet the specific needs of different healthcare settings.
Weaknesses
Phreesia faces intense competition in the healthcare technology sector, which puts pressure on pricing and may impact the company's market share. Additionally, Phreesia's reliance on third-party integrations and partnerships exposes it to potential disruptions or limitations in service provision.
Although Phreesia has built a solid reputation, some potential clients may still be skeptical about adopting new technological solutions, leading to slower adoption rates and longer sales cycles.
Opportunities
The increasing demand for digitization and automation in healthcare presents Phreesia with significant growth opportunities. The company can expand its offerings to include additional modules and features, such as telehealth integrations and remote patient monitoring, to stay ahead of market trends.
Furthermore, Phreesia can explore partnerships with key industry stakeholders, such as electronic medical record (EMR) providers, to integrate its solutions seamlessly into existing healthcare ecosystems. This collaboration can enhance Phreesia's market reach and open doors for cross-selling opportunities.
Threats
One of the potential threats for Phreesia is the presence of well-established competitors with similar products and services. The market entry of new disruptive technologies or the emergence of alternative solutions could also pose a challenge to Phreesia's market position and growth prospects.
Additionally, regulatory changes in the healthcare industry, such as privacy and security requirements, may impose compliance burdens on Phreesia. Non-compliance or data breaches could damage the company's reputation and result in legal and financial consequences.
Phreesia Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
Phreesia Segments
Phreesia Revenue by Segment
3 Years
5 Years
Max
Details
Phreesia Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Phreesia historical P/E ratio, EBIT multiple, and P/S ratio
Phreesia annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Phreesia shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Phreesia Dividend History
7 years of dividend payments
Current Phreesia forecasts and price targets in August 2026
Analyst Price Targets 2026Phreesia Analyst Rating Actions
| Date | Firm | Action | Rating | Reliability |
|---|---|---|---|---|
| 5/29/2026 | Maintained | Hold | – | |
| 5/28/2026 | Maintained | Buy | – | |
| 5/28/2026 | Maintained | Neutral | 48 | |
| 5/28/2026 | Maintained | Buy | 59 | |
| 5/20/2026 | Downgrade | OverweightEqual Weight | 56 | |
| 5/15/2026 | Downgrade | OverweightEqual Weight | 33 | |
| 4/13/2026 | Maintained | Overweight | 49 | |
| 4/1/2026 | Downgrade | Market OutperformMarket Perform | – | |
| 3/31/2026 | Downgrade | BuyHold | – | |
| 3/31/2026 | Maintained | Overweight | – |
Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.
Phreesia Earnings Calls
Phreesia Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 5/27/2026 | 0.01USD | - | 131.43 MUSD | - | 2027 Q1 |
| 3/30/2026 | 0.07USD | - | 127.99 MUSD | - | 2026 Q4 |
| 12/8/2025 | 0.00USD | - | 121.25 MUSD | - | 2026 Q3 |
| 12/9/2024 | -0.27USD | - | 107.31 MUSD | - | 2025 Q3 |
| 5/29/2024 | -0.16USD | - | 102.78 MUSD | - | 2025 Q1 |
| 3/20/2024 | -0.35USD | - | 95.87 MUSD | - | 2024 Q4 |
| 12/6/2023 | -0.39USD | - | 94.18 MUSD | - | 2024 Q3 |
| 5/31/2023 | -0.57USD | - | 82.45 MUSD | - | 2024 Q1 |
| 3/28/2023 | -0.59USD | - | 73.27 MUSD | - | 2023 Q4 |
| 12/8/2022 | -0.61USD | - | 71.95 MUSD | - | 2023 Q3 |
EESG©
Eulerpool ESG Scorecard© for the Phreesia stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Phreesia shareholder structure
| % | Name |
|---|---|
9.46224% | |
5.19966% | |
2.28349% | |
1.02843% | |
0.88021% | |
0.83823% |
Phreesia Beneficial Ownership Filings (SEC 13D/G)
| Stake | Holder | Filing |
|---|---|---|
14.70% | SEC ↗ | |
11.70% | SEC ↗ | |
7.00% | SEC ↗ | |
6.77% | SEC ↗ | |
6.60% | SEC ↗ | |
5.80% | SEC ↗ | |
5.80% | SEC ↗ | |
5.77% | SEC ↗ | |
5.60% | SEC ↗ | |
4.70% | SEC ↗ |
Phreesia Executives and Management Board
13 members · avg. age 56 · 38 % women
Mr. Chaim Indig (45)
Chief Executive Officer, Director · since 2005
10.51 M USD
Management
Mr. Balaji Gandhi (51)
Chief Financial Officer
Mr. Evan Roberts (46)
Chief Operating Officer
Mr. David Linetsky (45)
Senior Vice President - Network Solutions
Ms. Allison Hoffman (53)
General Counsel, Secretary
Ms. Amy VanDuyn (51)
Senior Vice President - Human Resources
Board of Directors
Mr. Michael Weintraub (66)
Independent Chairman of the Board
Ms. Gillian Munson (54)
Independent Director
Dr. Mark Smith (73)
Independent Director
Ms. Lainie Goldstein (57)
Independent Director
Mr. Ramin Sayar (52)
Independent Director
Mr. Edward Cahill (72)
Independent Director
Phreesia Supply Chain
Phreesia Supply Chain
Correlation: how closely stock prices move together
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | 0.81 | 0.91 | 0.55 | ||
| 2 | 0.76 | 0.66 | 0.54 | ||
| 3 | 0.92 | 0.90 | 0.43 | ||
| 4 | 0.93 | 0.95 | 0.36 |
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | 0.95 | 0.89 | — | ||
| 2 | 0.86 | — | — | ||
| 3 | -0.66 | -0.90 | -0.42 | ||
| 4 | -0.58 | -0.85 | 0.07 | ||
| 5 | -0.28 | -0.75 | 0.08 |
Frequently asked questions about Phreesia
The business model of Phreesia Inc is centered around providing patient intake and engagement solutions to healthcare organizations. By offering a comprehensive platform, Phreesia streamlines the registration process, collects patient information, verifies insurance eligibility, and facilitates payments. Their services aim to enhance operational efficiency, improve patient experience, and drive revenue growth for clients. Through innovative technology and data analytics, Phreesia empowers healthcare providers to effectively streamline their workflows, optimize patient care, and increase financial performance. The company focuses on delivering value to healthcare organizations by improving the patient journey and enabling a better patient-provider relationship.
Phreesia Inc is primarily active in the healthcare industry.
Some of the main competitors of Phreesia Inc in the market include athenahealth, Cerner Corporation, and athenathealth.
Phreesia Inc is a leading healthcare technology company that specializes in patient intake solutions. Founded in 2005, Phreesia has revolutionized the way healthcare organizations collect patient information, automate workflows, and enhance the patient experience. With their innovative platform, Phreesia has helped thousands of healthcare providers streamline their operations and improve patient engagement. By offering a patient-centric approach, Phreesia has become a trusted partner in the industry, empowering healthcare organizations to deliver high-quality care while reducing administrative burdens. With a strong track record of success and a commitment to innovation, Phreesia continues to be at the forefront of transforming healthcare delivery.
Phreesia Inc has achieved several significant milestones over the years. One of the notable achievements is their successful initial public offering (IPO) in July 2019, which allowed the company to raise substantial capital to fuel their growth. Furthermore, Phreesia has consistently expanded its client base, forging partnerships with numerous leading healthcare organizations across the United States. The company's innovative platform, which streamlines patient intake and payment processes, has garnered recognition and accolades, including being named one of the "50 Most Innovative Companies" by Fast Company in 2020. Phreesia's commitment to driving healthcare efficiency and enhancing patient experiences has positioned them as a prominent player in the industry.
Phreesia Inc is primarily present in the United States.
Phreesia Inc is a healthcare technology company that aims to improve patient experiences and streamline administrative tasks. With a focus on innovation and efficiency, Phreesia provides a comprehensive platform for healthcare providers to manage patient intake, payments, and engagement. The company's corporate philosophy revolves around empowering patients, enhancing clinical decision-making, and improving healthcare outcomes. By leveraging cutting-edge technology and patient-centric solutions, Phreesia strives to revolutionize the healthcare industry. Through its robust platform and commitment to delivering a seamless experience, Phreesia Inc showcases a dedication to advancing patient care and transforming the healthcare landscape.
Analysts currently set an average price target of 29.20 USD for the Phreesia stock (median: 28.56 USD), implying +172.2 % versus the latest price. The consensus is based on 24 analyst ratings.
24 analysts currently rate the Phreesia stock: 23 recommend buying, 1 holding and 0 selling.
Converted at the current exchange rate, the Phreesia share trades at 9.32 EUR (10.73 USD).
The Phreesia share (PHR) is listed on 5 stock exchanges, including: NYSE (PHR), Frankfurt (19P.F), München (19P.MU), London (0A23.L), London (0A23.L).
Phreesia Inc is a provider of technology-enabled services that optimize and improve patient traffic in medical practices and healthcare clinics. The company was founded in 2005 and is headquartered in New York City. Phreesia offers a wide range of services, such as patient registration, data entry, insurance verification, bill payment, appointment scheduling, and patient feedback. One of the company's most innovative products is the PhreesiaPad, an electronic tablet that automates paperwork during patient registration in the doctor's office. Phreesia has focused on the outpatient healthcare market, particularly medical practices and health centers, and has garnered numerous large clients, such as NewYork-Presbyterian Hospital and Duke University Medical Center. The company has developed comprehensive software that serves as the interface between physicians, insurance companies, and patients. Phreesia's core business is a subscription model, where customers pay a monthly fee to access the various services offered by the company. The company also partners with insurance companies to directly offer their services to patients. This leads to greater cost transparency and facilitates collaboration between physicians and insurance companies. Phreesia recently invested in telemedicine by partnering with SimplyWell, a digital health coaching company. This partnership allows Phreesia to offer a comprehensive platform for telemedicine and digital health solutions. Overall, Phreesia has developed a business model that enables easier collaboration and improves communication and transparency between physicians, patients, and insurance companies. By providing a comprehensive software solution that takes into account both the workflow in the practice and the requirements and expectations of patients, Phreesia has secured a solid position in the healthcare market.
The revenue of Phreesia is 473.64 M USD. This figure is based on current financial data and reflects the company's business performance.
The profit of Phreesia is 2.31 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Phreesia is currently 288.68. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Phreesia stock.
The price-to-sales ratio (P/S) of Phreesia is currently 1.41. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Phreesia stock.
The Eulerpool Quality Score for Phreesia is 4/10.
The ISIN of Phreesia is US71944F1066. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Phreesia is A2PMY3. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Phreesia is PHR. The ticker symbol is used to trade Phreesia shares on the stock exchange.
Phreesia pays a dividend, distributed in the months of , , , .
Phreesia paid dividends every year for the past 0 years.
Phreesia is assigned to the 'Health' sector.
To receive the latest dividend of Phreesia from amounting to 0.58 USD, you needed to have the stock in your portfolio before the ex-date on .
The last dividend was paid out on .
The dividends of Phreesia are distributed in USD.
Phreesia stock
Phreesia Peer Group
Phreesia Ticker
Phreesia FIGI
All fundamentals and in-depth analysis of Phreesia
Our stock analysis for Phreesia stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Phreesia. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.